Standout Papers

Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients wi... 2020 2026 2022 2024174
  1. Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (2020)
    Xinan Sheng, Xieqiao Yan et al. Clinical Cancer Research

Immediate Impact

4 by Nobel laureates 8 from Science/Nature 57 standout
Sub-graph 1 of 23

Citing Papers

One‐Step Symbiosis of Bimetallic Peroxides Nanoparticles to Induce Ferroptosis/Cuproptosis and Activate cGAS‐STING Pathway for Enhanced Tumor Immunotherapy
2025 Standout
De novo design of allosterically switchable protein assemblies
2024 StandoutNatureNobel
2 intermediate papers

Works of Jun Guo being referenced

A phase III randomized open label study comparing bempegaldesleukin (NKTR-214) plus nivolumab to sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma.
2019
Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients
2018

Author Peers

Author Last Decade Papers Cites
Jun Guo 2169 1628 627 801 201 3.3k
Xinan Sheng 2123 1459 474 712 185 3.1k
Salvador Martín‐Algarra 2212 1319 906 1110 141 3.8k
Luis de la Cruz‐Merino 2484 1889 669 776 171 3.8k
Michele Guida 2109 1135 670 877 145 3.1k
Marco Danova 1599 1110 561 512 222 3.5k
Iván Márquez‐Rodas 2911 1315 757 1192 120 3.9k
Sapna P. Patel 1696 1470 455 1194 205 3.4k
Romain Boidot 1614 1734 463 1222 112 3.9k
Corrado Caracò 2159 864 380 775 142 3.2k
Thomas Olencki 1991 1515 1701 872 120 3.8k

All Works

Loading papers...

Rankless by CCL
2026